Clinical trials: Diabetes Type I
Type 1 Diabetes, Type 2 Diabetes
Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices
The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.
- Trial name
- NCT04020822
- Testing
- Guardian Sensor (3)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
The purpose of this study is to investigate the effect of using FreeStyle InsuLinx (a blood glucose meter with a built-in insulin calculator) on glucose control in people with type 1 diabetes.
- Trial name
- NCT01519466
- Testing
- FreeStyle InsuLinx, FreeStyle Freedom Lite
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 55 people
- Sponsor
- Abbott Diabetes Care
Diabetes Mellitus, Type 1
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Investigator initiated, randomised, placebo-controlled, double-blind, multi-centre primary intervention study to assess whether daily administration of B.
- Trial name
- SINT1A (NCT04769037)
- Testing
- B. infantis
- Where
- 8 sites in Belgium, Germany and 3 more
- Volunteers
- 1,149 people, healthy volunteers welcome
- Sponsor
- Helmholtz Zentrum München
Type 1 Diabetes
Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)
A prospective, single-arm study of 13 weeks of home use of the t:slim X2 insulin pump with Control-IQ technology in individuals with type 1 diabetes who will plan to use at least one basal rate > 3 units/hr.
- Trial name
- NCT05422053
- Testing
- t:slim X2 insulin pump with Control-IQ technology 1.5
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Europe, Oceania, and the United States of America (USA). The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart (IDegAsp)) with insulin detemir (IDet) plus insulin aspart…
- Trial name
- BOOST™ (NCT00978627)
- Testing
- insulin degludec/insulin aspart, insulin detemir, insulin aspart
- Where
- 81 sites in United States, Australia and 8 more
- Volunteers
- 548 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of the trial is to evaluate continuous subcutaneous infusion of NN1218 formulations and NovoLog® in subjects with type 1 diabetes.
- Trial name
- NCT01682902
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics
This trial is conducted in Europe. The aim of this clinical trial is to compare the blood glucose lowering effect of NN5401(insulin degludec/insulin aspart (IDegAsp)) with NN1250 (insulin degludec (IDeg)) and insulin aspart…
- Trial name
- NCT00992537
- Testing
- insulin degludec, insulin degludec/insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Healthy Male Volunteers
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX13 with YERVOY® Injection in Healthy Chinese Male Subjects
- Trial name
- NCT06159101
- Testing
- HLX13, CN-sourced ipilimumab, EU-sourced ipilimumab group
- Where
- China
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Shanghai Henlius Biotech
Type 1 Diabetes Mellitus
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
- Trial name
- NCT03849612
- Testing
- AID System, Insulin Lispro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Atherosclerosis, Diabetes Mellitus
TART - Troglitazone Atherosclerosis Regression Trial
The purpose of this study is to determine if troglitazone reduces the progression of early preintrusive carotid atherosclerosis in insulin-requiring diabetes patients.
- Trial name
- NCT00116545
- Testing
- troglitazone
- Where
- United States
- Volunteers
- 288 people
- Sponsor
- Parke-Davis
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) properties of FIAsp…
- Trial name
- NCT01924637
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Austria
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is…
- Trial name
- NCT03723772
- Testing
- Insulin icodec, IGlar U100
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2, Diabetes Mellitus Type 1
A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.
German Multi-centered, randomized, crossover study in diabetic patients evaluating two infusion sets under real life conditions at home.
- Trial name
- NCT02103595
- Testing
- Accu-Chek FlexLink, Accu-Chek FlexLink Plus
- Where
- 5 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
The purpose of this study is to collect information on how NovoPen® 6 works with Tresiba® \& Fiasp® for treatment of people with type 1 diabetes and see if the use of NovoPen® 6 can help participants achieve better blood sugar…
- Trial name
- CONNECT 1 (NCT05069545)
- Testing
- Insulin degludec, Fast-acting insulin aspart
- Where
- 26 sites in Belgium, Denmark and 2 more
- Volunteers
- 411 people
- Sponsor
- Novo Nordisk A/S
Type I Diabetes
Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics
This is an open label, randomized, parallel group comparison of the immunogenicity safety of Wockhardt's human insulin and isophane insulin compared with the Novo Nordisk's yeast based human insulin products (marketed in USA) in…
- Trial name
- NCT01308437
- Testing
- Wosulin (N or 70/30 with R), Novolin® (N or 70/30 with R)
- Where
- 25 sites in United States, India
- Volunteers
- 134 people
- Sponsor
- Wockhardt
Type 1 Diabetes
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
- Trial name
- NCT06144554
- Testing
- Omnipod 5
- Where
- United States
- Volunteers
- 2,200 people
- Sponsor
- Insulet Corporation
Diabetes, Diabetes Mellitus, Type 1 Diabetes
Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device
The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant's previous insulin treatment.
- Trial name
- GoBolus (NCT03450863)
- Testing
- Fast-acting insulin aspart
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
The purpose of this study to assess the safety and tolerability of re-dosing at 6 months with otelixizumab (given as an 8-day series of intravenous infusions) in adult subjects with newly diagnosed type 1 diabetes mellitus
- Trial name
- NCT01222078
- Testing
- otelixizumab
- Where
- 2 sites in France, Germany
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Non-insulin-dependent Diabetes Mellitus
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration of the study will be approximately 60 weeks.
- Trial name
- NCT00231387
- Testing
- rosiglitazone
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.